CommunityConnect with experts, uncover more opportunities
2.07K
General
Tiger V
·
2025-08-18
$Apple(AAPL)$ I added to my Apple (AAPL) position following Morgan Stanley’s bullish iPhone forecast upgrade, now expecting 54M units in the September quarter versus 50M previously. The revision reflects pent-up replacement demand, stronger designs, and margin improvements. Importantly, peak tariff concerns have eased while regulatory impacts remain softer than feared. With services pricing yet to be adjusted in two years, Apple holds untapped growth potential. Valuation relative to the S&P 500 remains fair, and upward estimate revisions historically drive multiple expansion, strengthening my conviction in Apple’s sustained growth trajectory.
AAPL
08-18 21:49
USApple
SidePrice | FilledRealized P&L
Buy
Open
232.37
0
--
Closed
Apple
$Apple(AAPL)$ I added to my Apple (AAPL) position following Morgan Stanley’s bullish iPhone forecast upgrade, now expecting 54M units in the Septem...
1
Report
612
General
一追再追
·
2025-08-18
$SMMT 20250822 25.0 PUT$ 我看好賣出SMMT $25認沽期權的策略,即便被行權接貨,安全邊際依然極高。從基本面看,SMMT專注於開發ivonescimab(雙特異性抗體),在非小細胞肺癌(NSCLC)治療中展現競爭力。2025年Q1財報顯示,現金及短期投資達3.613億美元,無重大長期債務,財務穩健(流動資產為短期負債的2.13倍)。儘管Q1淨虧損6290萬美元(每股-0.09美元),但其臨床進展亮眼:HARMONi-6試驗顯示ivonescimab聯合化療在NSCLC中進展自由存活期(PFS)顯著優於對照組,獲中國NMPA批准,潛在峰值年收入達100億美元。產品競爭力獲市場認可,與阿斯利康洽談150億美元授權交易進一步提升估值空間。 從估值角度,SMMT當前股價26.29美元(截至2025年8月18日),市淨率(P/B)約為高位,但DCF模型估計內在價值遠超當前價格(WallStreetZen估計合理價值僅0.18美元,但分析師平均目標價34.73美元,潛在上漲64.6%)。技術分析顯示,$25為一年內關鍵支撐位(52周低點2.10美元,高點36.91美元),近期RSI(57.33)處中性,CCI(11.65)未超買,短期波動後反彈概率高。行業趨勢方面,生物科技與免疫療法市場2025-2030年預計CAGR超10%,SMMT的全球試驗與合作強化其領先地位。 即便期權被行權,$25的接貨價遠低於分析師目標價(最高44美元),結合穩健現金流與臨床催化劑,風險可控,長期獲利空間廣闊。此策略兼具防守性(低估值支撐)與進攻性(臨床與合作催化),安全邊際顯著。
SMMT PUT
08-18 22:59
US20250822 25.0
SidePrice | FilledRealized P&L
Sell
Open
0.45
3Lot(s)
--
Closed
Summit Therapeutics PLC
$SMMT 20250822 25.0 PUT$ 我看好賣出SMMT $25認沽期權的策略,即便被行權接貨,安全邊際依然極高。從基本面看,SMMT專注於開發ivonescimab(雙特異性抗體),在非小細胞肺癌(NSCLC)治療中展現競爭力。2025年Q1財報顯示,現金及短期投資達3.613億...
Comment
Report
1.13K
General
著名垃圾級基金經理
·
2025-08-18
$FIG 20250829 65.0 PUT$ Figma財務表現亮眼,2024財年(截至2025年1月)營收7.49億美元,同比增長48%,LTM營收超8.2億美元。2025財年Q1實現4490萬美元淨利,展現“增長+盈利”雙贏。账面現金超15億美元,幾無長期債務,包括Adobe支付的10億美元解約金,為AI投資與平台建設提供資金支持。Figma開創雲端SaaS+實時協作模式,解決傳統設計軟件痛點,採用“增值免費”策略,吸引1300萬註冊用戶,2024財年毛利率達91%。其插件與模板生態增強用戶粘性。儘管AI浪潮帶來依賴第三方模型、數據合規及同質化競爭風險,Figma積極布局AI,長期成長潛力巨大。當前股價下跌或為短期波動,未來前景依然樂觀。我沽出認沽期權做好。
FIG PUT
08-18 23:28
US20250829 65.0
SidePrice | FilledRealized P&L
Sell
Open
0.65
1Lot(s)
--
Closed
Figma
$FIG 20250829 65.0 PUT$ Figma財務表現亮眼,2024財年(截至2025年1月)營收7.49億美元,同比增長48%,LTM營收超8.2億美元。2025財年Q1實現4490萬美元淨利,展現“增長+盈利”雙贏。账面現金超15億美元,幾無長期債務,包括Adobe支付的10億...
1
Report
4.93K
Hot
Shernice軒嬣 2000
·
2025-08-18

Citron Research just announced a short call on #Palantir

OpenAI’s recent employee share sale valued the company at $500B, with projected 2026 revenue of $29.6B → Forward P/S = 16.9x. Wall Street expects Palantir’s 2026 revenue at $5.6B. Using OpenAI’s multiple, Palantir’s fair value should be about $95B. But Palantir’s market cap is already $412B+ — meaning its “fair” stock price should be closer to $40. OpenAI is actually growing revenue faster than Palantir, and Citron argues Palantir’s real rival is Databricks (still private). Palantir currently trades at the highest valuation multiple in the S&P 500. Stocks can stay irrationally priced for a long time, but this gap is huge. Also, institutional ownership is relatively low compared to other SaaS names — so shorting means going head-to-head with retail bulls.
Citron Research just announced a short call on #Palantir
TOP麥卡倫 18: I am looking forward to witness you short it to $40.
11
Report
1.76K
General
Barcode
·
2025-08-19
🌌🚀🎭 From Theta Decay to Kopi Breaks: My Tribute to my special SG 🇸🇬 Sis Space Rocket 🎭🚀🌌 🌟🌟🌟🚀 Sis, your Star Contributor feature wasn’t just a profile; it was like reading the transcript of a perfectly executed straddle: balanced, bold, and paying off on both sides. I’m so grateful for the shout-out, but even more grateful for the hours you poured into me through personal emails and late-night messages when I was learning options. While others would’ve said “aiya, too suay, give up lah,” you broke down Greeks patiently, rolled me through strategies like a pro, and kept me laughing when volatility made me want to margin-call myself. That kind of generosity is rarer than finding vega in a value stock. Your journey shines with resilience! 🤩 Losing USD $22K on SEV would’ve grounded most trader

@SPACE ROCKET: More Than a Trader: A Mother’s Journey of Growth and Grit

@TigerClub
Meet @SPACE ROCKET — a star contributor in the Tiger Community. — Meet Space Rocket, a mother of two and a passionate trader. Inspired by her grandfather’s legacy, she turned early setbacks into resilience, growing her portfolio 4X with a 452% RoR. Today, she balances family life with trading, teaching her sons financial literacy while building her legacy in the markets.Want to know her real-time trading? Click to view her trading information, and subscribe to receive her real-time trading signal!Join in the interaction section at the end of the article! Leave a comment and everyone has the chance to win STOCK VOUCHERS and Tiger coins!Could you br
@SPACE ROCKET: More Than a Trader: A Mother’s Journey of Growth and Grit
🌌🚀🎭 From Theta Decay to Kopi Breaks: My Tribute to my special SG 🇸🇬 Sis Space Rocket 🎭🚀🌌 🌟🌟🌟🚀 Sis, your Star Contributor feature wasn’t just a profi...
TOPHen Solo: I thought this was a wonderful tribute to Space Rocket, tying her contrarian plays like SIA at $3 with her risk discipline. Holding 40% cash before seasonal dips reminds me of capital allocation strategies Buffett applied in BRK. It’s inspiring to see friendships like yours proving markets connect us worldwide.
3
Report
1.86K
Selection
Barcode
·
2025-08-19

📈🧬🚀 Aligos Therapeutics: Analyst Upgrade, $50 Price Target, and HBV Breakthrough Potential 🚀🧬📈

$Aligos Therapeutics, Inc.(ALGS)$ $Gilead Sciences(GILD)$ $Arbutus Biopharma(ABUS)$ 🧪 Clinical conviction with ALG-000184 I’m fully convinced $ALGS (Aligos Therapeutics) is one of the most misunderstood small-cap biotech setups in the market. I’ve held this position for a long time because of my personal conviction in their science and its potential impact on someone I care about who struggles with liver disease. I’m confident Phase 2 B-SUPREME is the core catalyst. With regulatory approvals across multiple countries, ~200 patients enrolled, and Phase 1 data showing significant HBV DNA reductions after 96 weeks, this program has durability and credibility. It’s n
📈🧬🚀 Aligos Therapeutics: Analyst Upgrade, $50 Price Target, and HBV Breakthrough Potential 🚀🧬📈
TOPTui Jude: 🧬What stands out is how you framed $ALGS around long-term optionality rather than just hype. Institutions love that durability. It’s clear you’re invested because the science is backed by fundamentals, not fluff, and that conviction separates this from retail chatter.
5
Report
2.02K
General
nomadic_m
·
2025-08-19
Both $POP MART(09992)$ and $XIAOMI-W(01810)$ have impressive growth prospects! Popmart's globalization strategy is paying off, with overseas revenue expected to surpass domestic revenue. Xiaomi's diversified business segments, including smartphones and EVs, are driving strong revenue growth. Personally, I think Xiaomi's stable growth trajectory makes it a more reliable choice, but Popmart's potential for explosive growth can't be ignored 🤔💸
@SPACE ROCKET
Not sure. So I googled for the following: ❤️Popmart (9992.HK)❤️ Popmart is set to release its first-half financial report on August 19, 2025. The company has already provided a positive profit warning, and analysts are highly optimistic about the results. The key theme is the company's successful globalization strategy. Revenue Analysts expect significant year-over-year revenue growth. Bloomberg forecasts revenue of 13.76 billion yuan for the first half of 2025, which would represent a 201.9% year-on-year increase. Profit The company has already stated that it expects profit to grow by no less than 350% year-on-year. Adjusted net profit is anticipated to exceed 4.6 billion yuan, which would be more than the company's full-year profit for 2024. Key Growth Drivers 1. Overseas Expansion
Not sure. So I googled for the following: ❤️Popmart (9992.HK)❤️ Popmart is set to release its first-half financial report on August 19, 2025. The company has already provided a positive profit warning, and analysts are highly optimistic about the results. The key theme is the company's successful globalization strategy. Revenue Analysts expect significant year-over-year revenue growth. Bloomberg forecasts revenue of 13.76 billion yuan for the first half of 2025, which would represent a 201.9% year-on-year increase. Profit The company has already stated that it expects profit to grow by no less than 350% year-on-year. Adjusted net profit is anticipated to exceed 4.6 billion yuan, which would be more than the company's full-year profit for 2024. Key Growth Drivers 1. Overseas Expansion
Both $POP MART(09992)$ and $XIAOMI-W(01810)$ have impressive growth prospects! Popmart's globalization strategy is paying off, with overseas revenu...
TOPHappiness.: ‌$POP MART(09992)$ ‌is cool i hope to visit when i am in China next month <3
6
Report
3.83K
Selection
Barcode
·
2025-08-19

🔥🇺🇸💾 Intel’s 10% Federal Stake Talks Ignite a Liquidity Reset: Is This Dilution or the Start of a Strategic Revival? 💾🇺🇸🔥

$Intel(INTC)$ $NVIDIA(NVDA)$ $Palantir Technologies Inc.(PLTR)$ I believe Intel has entered the most pivotal moment of its modern history. Reports confirm the Trump administration is negotiating a 10 % equity stake through Chips Act conversion, and I’m extremely confident this marks a profound credibility reset for the U.S. semiconductor landscape. While the market sold off on dilution fears, I’m convinced this liquidity flush will define Intel’s trajectory over the next decade. Chart Breakdown I’m watching the demand zone between $22.00 and $22.80, where repeated rebounds signal institutional defense. The daily chart shows Intel piercing through EMA 13 ($22.50),
🔥🇺🇸💾 Intel’s 10% Federal Stake Talks Ignite a Liquidity Reset: Is This Dilution or the Start of a Strategic Revival? 💾🇺🇸🔥
TOPTui Jude: Thanks for another great article, BC! I’m getting in buying the dip. ⚡ The Tepper angle is fascinating, $179M is no small endorsement and lining that with Trump’s push for Ohio fabs feels like a liquidity flush with teeth. I see why you’re watching $23.80, similar setups in $AMD before it doubled played off almost the same valuation imbalance.
7
Report
1.07K
Selection
nerdbull1669
·
2025-08-19

Baidu (BIDU) Earnings To Watch Cost Reduction and Results From Heavy AI Investment

$Baidu(BIDU)$ is scheduled to report its fiscal Q2 2025 earnings before the market opens on August 20, 2025. Here is an analysis of what investors should be watching and potential trading opportunities. Overall Revenue : The consensus revenue forecast is around $4.06 billion, which would represent a decline year-over-year. Earnings Per Share (EPS) : The consensus EPS forecast is around $1.32, which is also a significant drop from the prior year. The market's reaction will heavily depend on whether Baidu beats or misses these consensus estimates and, more importantly, the company's guidance for the rest of the year. Tipranks is expected the EPS to come in at around $1.84. Based on Baidu's fiscal Q1 2025 earnings report, which was released on May 21
Baidu (BIDU) Earnings To Watch Cost Reduction and Results From Heavy AI Investment
TOPVenus Reade: I'm still holding BIDUD and will for awhile. Maybe I'm delusional but it seems way under valued. As any good value investor knows you are supposed to hold under valued companies and eventually the market will realize their true value.
4
Report
5.28K
General
ToNi
·
2025-08-19
$UnitedHealth(UNH)$ Seize the Moment: Why UnitedHealth (UNH) at $300 is a Golden Ticket to Wealth in 2025 In the grand theater of Wall Street, where fortunes are made and lost with the flick of a ticker, a new star has emerged on the horizon—UnitedHealth Group (UNH). As of August 19, 2025, whispers of a “last call to buy at $300” are electrifying the X posts, and for good reason. Warren Buffett’s Berkshire Hathaway, the Oracle of Omaha himself, has thrown his weight behind UNH, snagging 5.039 million shares at an average of $314 per share in Q2 2025, a stake now valued at $1.57 billion. This isn’t just a stock pick; it’s a masterstroke, a beacon for savvy investors to ride the wave of a healthcare giant poised for a glorious ascent. Let’s dive into
$UnitedHealth(UNH)$ Seize the Moment: Why UnitedHealth (UNH) at $300 is a Golden Ticket to Wealth in 2025 In the grand theater of Wall Street, wher...
TOPMaurice Bertie: Buffett bought at $314,$300 UNH? Snatching this up!
3
Report
3.34K
General
ToNi
·
2025-08-19
Bitcoin at $115K: The Cosmic Dip That Could Ignite a Galactic Bull Run As the digital cosmos trembles, Bitcoin has plummeted to $115,000, a dramatic swoon from its dazzling new all-time high near $125,000 last week—its fourth celestial ascent of 2025. With $570 million in liquidations unleashed by profit-taking zealots in the past 24 hours, the crypto galaxy is buzzing with a primal question: Is this a healthy dip to buy, or the prelude to a bull run’s spectacular crash? As of 11:17 AM NZST on August 19, 2025, I’m here to argue a bold, electrifying thesis: this dip is not just a buying opportunity—it’s the gravitational pull igniting a galactic bull run, propelled by a cosmic convergence of quantum adoption, macro defiance, and human greed. Buckle up, stargazers, for a journey beyond the c
Bitcoin at $115K: The Cosmic Dip That Could Ignite a Galactic Bull Run As the digital cosmos trembles, Bitcoin has plummeted to $115,000, a dramati...
TOPMaurice Bertie: This dip’s fuel! $150K by year-end? Strap in, it’s happening.
3
Report
4.50K
General
ToNi
·
2025-08-19

EVOK: The Nasal Revolution Igniting a Biotech Firestorm – Buy Before It Explodes!

In the shadowy underbelly of biotech, where giants like Pfizer and Moderna hog the spotlight with their billion-dollar vaccines, a pint-sized rebel is brewing a storm that could redefine gastrointestinal care. Evoke Pharma (NASDAQ: EVOK), trading at a tantalizing $5.96 as of August 18, 2025, isn’t just a stock—it’s a ticking time bomb of innovation, poised to detonate in the face of a $10 billion diabetic gastroparesis market. Forget the cookie-cutter pharma plays; EVOK’s Gimoti nasal spray is the guerrilla warrior bypassing broken digestive systems, delivering relief where pills fail. With Q2 2025 sales skyrocketing 47% to $3.752 million and analysts eyeing an $18 target (a 200%+ upside), this micro-cap dynamo is the ultimate contrarian bet. Buckle up: EVOK isn’t riding the wave—it’s the
EVOK: The Nasal Revolution Igniting a Biotech Firestorm – Buy Before It Explodes!
TOPReg Ford: EVOK’s 200% upside? Gimoti’s sales surge,snatching shares now!
3
Report
1.17K
Selection
nerdbull1669
·
2025-08-19

iQIYI (IQ) Earnings To Focus On Membership and Advertising Revenue For Path To Profitability

$iQiyi Inc.(IQ)$ is scheduled to report its fiscal Q2 2025 earnings before the U.S. market opens on August 20, 2025. Here is an analysis of what investors should be watching and potential trading opportunities. Analyst Expectations: The consensus EPS forecast for Q2 2025 is around a loss of $-0.04 per share. This low bar, combined with a history of mixed earnings surprises, could create an opportunity for a positive surprise. A better-than-expected result, particularly on the subscriber or revenue front, could trigger a short-term rally. Summary of iQIYI (IQ) Fiscal Q1 2025 Earnings On May 21, 2025, iQIYI released a mixed bag of results for its fiscal Q1 2025. While the company saw a sequential improvement in some key metrics, the year-over-year per
iQIYI (IQ) Earnings To Focus On Membership and Advertising Revenue For Path To Profitability
TOPMortimer Arthur: I'm a chart trader. Watch the patterns and trends. This one literally has possibilities to peak at 4, 5, 6, 7, 8 9, and 10.
5
Report
4.61K
General
Shyon
·
2025-08-19
I was excited to see the recent news about Berkshire Hathaway $Berkshire Hathaway(BRK.A)$  , led by Warren Buffett, releasing its 13F filing for the second quarter of 2025 today. The highlight for me was that Berkshire initiated a new position in U.S. health insurance giant UnitedHealth$UnitedHealth(UNH)$  , purchasing 5.039 million shares for about $1.6 billion. The average purchase price was $314 per share, and by the end of the quarter, the position was valued at $1.57 billion, making it the 18th largest holding in Berkshire's portfolio—just behind Amazon and $Constellation(STZ)$  . This move by Buffett, a legendary
I was excited to see the recent news about Berkshire Hathaway $Berkshire Hathaway(BRK.A)$ , led by Warren Buffett, releasing its 13F filing for the...
TOPBerniceCarter: What a brilliant move by Buffett! [Wow]
2
Report
1.16K
General
Tiger V
·
2025-08-19

Markets Hold Steady Ahead of Jackson Hole and Geopolitical Talks

Overall Market Overview Global markets ended the week with muted movements as investors awaited pivotal events, including US retail earnings and Fed Chair Jerome Powell’s speech at the Jackson Hole summit. While US equities were nearly flat, Europe delivered a mixed performance, and Asia generally closed higher on optimism surrounding geopolitical discussions. US: Investors in Wait-and-See Mode US stocks ended largely unchanged, with the Dow Jones $DJIA(.DJI)$  slipping 34.30 points to 44,911.82 and the S&P 500 $S&P 500(.SPX)$  easing 0.65 points to 6,449.15. Investors held back major moves ahead of retail earnings reports and
Markets Hold Steady Ahead of Jackson Hole and Geopolitical Talks
1
Report
2.20K
General
Shyon
·
2025-08-19
I have been closely watching the recent movement in Bitcoin, and I find the drop to $115,000 after touching a new all-time high last week, near $125,000, quite interesting. This marks its fourth significant peak this year, and the subsequent pullback feels like a natural part of the cycle. The fact that investors' profit-taking triggered more than $570 million in liquidations over the past 24 hours does not surprise me; it seems like a healthy correction after such a strong run. I believe this is indeed a very healthy pullback before another rally. The market often needs these dips to shake out over-leveraged positions and reset sentiment, and the current level around $115,000 looks like a solid buying opportunity. Having seen Bitcoin recover from dips in the past, I am optimistic that thi
I have been closely watching the recent movement in Bitcoin, and I find the drop to $115,000 after touching a new all-time high last week, near $12...
TOPElsieDewey: It's great to see your positive outlook.
4
Report
922
General
Shyon
·
2025-08-19
I’m excited about $POP MART(09992)$ upcoming earnings, especially with overseas revenue likely surpassing 50% for the first time. The strong growth in the U.S., Europe, and Southeast Asia highlights Pop Mart’s shift from a domestic toy brand to a global cultural player. Labubu’s global popularity and the success of its cross-border IP strategy have been key drivers. Profitability is another area I’ll be watching closely. If gross margin reaches 70% and net margin expands past 30%, it would show Pop Mart is scaling efficiently while monetizing IP successfully. Co-branded hits like “Ne Zha 2” and upcoming partnerships with One Piece & Harry Potter could add further upside. That said, the stock already reflects high expectations. But if earni
I’m excited about $POP MART(09992)$ upcoming earnings, especially with overseas revenue likely surpassing 50% for the first time. The strong growth...
TOPfuddie: Love your enthusiasm for $POP MART! 🌟
4
Report
680
General
Mickey082024
·
2025-08-19

Lowe’s: A Dividend Growth Powerhouse in Retail That Smart Money Won’t Ignore

$Lowe's(LOW)$ Why billionaire investors are buying into Lowe’s, and whether it still offers long-term upside for dividend seekers and value-focused portfolios Performance Overview and Market Feedback Lowe’s has delivered enviable returns for long-term shareholders. A $1,000 investment made in the company ten years ago would now be worth around $3,424, excluding dividends. When dividend income of approximately $392 over the period is included, the total return rises to nearly $3,816 — a gain of more than 280% in a decade. That level of performance is impressive for a mature retailer. By comparison, Home Depot delivered a slightly higher return of around 340% during the same period, while the broader S&P 500 index advanced roughly 230%. Lowe’s ha
Lowe’s: A Dividend Growth Powerhouse in Retail That Smart Money Won’t Ignore
TOPAstrid Stephen: Lowe’s 2.1% yield + 15.9% dividend growth? Perfect for income!
4
Report
1.07K
General
Mickey082024
·
2025-08-19

The Trade Desk: After a 57% Collapse, Is Management Poised to Launch an Aggressive Buyback Program?

$Trade Desk Inc.(TTD)$ The Trade Desk (NASDAQ: TTD), one of the most prominent players in the digital advertising ecosystem, has endured a tumultuous year. Shares are now down more than 57% year-to-date in 2025, including a staggering 40% drop immediately following the release of its second-quarter earnings. For long-term shareholders, the decline has been both painful and puzzling, particularly given that the company continues to report solid revenue growth, healthy margins, and a pristine balance sheet. This raises an important question: has the market overreacted, or is there something more troubling beneath the surface? More importantly, how will The Trade Desk’s management team respond to this sharp dislocation in valuation? Based on financial
The Trade Desk: After a 57% Collapse, Is Management Poised to Launch an Aggressive Buyback Program?
TOPAthena Spenser: TTD’s 57% drop? Insane,fundamentals still rock, buying now!
3
Report
 
 
 
 

Most Discussed

 
 
 
 
 

7x24